{
    "nct_id": "NCT03486067",
    "official_title": "A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma",
    "inclusion_criteria": "* History of multiple myeloma with relapsed and refractory disease\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Must have measurable disease as determined by the central laboratory\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic central nervous system involvement of multiple myeloma\n* Prior autologous stem cell transplant ≤ 3 months prior\n* Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior\n* History of concurrent second cancers requiring active, ongoing systemic treatment\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}